Pharmacokinetics of aripiprazole and concomitant carbamazepine

Journal of Clinical Psychopharmacology

Volumn 27, Issue 3, 2007, Pages 279-283

  Citrome, Leslie ^a,b   MacHer, Jean Paul ^c   Salazar, Daniel E ^d   Mallikaarjun, Suresh ^e   Boulton, David W ^f  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Centre Hospitalier de Rouffach   (France)

^d DAIICHI SANKYO INC   (United States)

^e OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CYTOCHROME P450 3A4; DEHYDROARIPIPRAZOLE; DRUG METABOLITE;

AGITATION; ANXIETY; AREA UNDER THE CURVE; ARTICLE; AUDITORY HALLUCINATION; BACKACHE; BEHAVIOR DISORDER; BLOATING; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPEPSIA; ECZEMA; ENZYME SUBSTRATE; HALLUCINATION; HUMAN; IRRITABILITY; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MYALGIA; NERVOUSNESS; OPEN STUDY; PERSONALITY DISORDER; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SALIVATION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH DISEASE; TREATMENT DURATION; WEIGHT GAIN;

ADULT; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CARBAMAZEPINE; DRUG ANTAGONISM; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; SCHIZOPHRENIA;

EID: 34248545611     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/jcp.0b013e318056f309     Document Type: Article

References (17)

1. Citrome L, Jaffe A, Levine J. Datapoints - mood stabilizers: utilization trends in patients diagnosed with schizophrenia 1994-2001. Psychiatr Serv. 2002;53:1212.
2. Citrome L, Goldberg JF, Stahl SM. Towards convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry. 2005;13:28-42.
3. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry. 2000;61:9-15.
4. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to lithium or valproate monotherapy. Arch Gen Psychiatry. 2002;59:62-69.
5. Sachs G, Chengappa K, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, doubleblind, placebo-controlled study. Bipolar Disord. 2004;6:213-223.
6. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159:1146-1154.
7. Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry. 1999;156:1164-1169.
8. Weisler R, Dunn J, English P. Adjunctive ziprasidone for bipolar mania: short and long-term data. Int J Neuropsychopharmacol. 2004;7(suppl 1):S327.
9. Citrome L, Josiassen R, Bark N, et al. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol. 2005;45:89-93.
10. McNamara JO. Chapter 21: drugs effective in the therapy of the epilepsies. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001:533-534.
11. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400-1411.
12. Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother. 2003;37:687-694.
13. Bristol-Myers Squibb Company. Abilify (aripiprazole) tablets, Abilify (aripiprazole) oral solution. In: Physicians' Desk Reference. 60th ed. Montvale, NJ: Thomson PDR; 2006:916-922.
14. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv. 2000;51:634-638.
15. Fenn HH, Robinson D, Luby V, et al. Trends in pharmacotherapy of schizoaffective and bipolar affective disorders: a 5-year naturalistic study. Am J Psychiatry. 1996;153:711-713.
16. Weisler RH, Hirschfeld R, Cutler AJ, et al. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs. 2006;20:219-231.
17. Levine J, Chengappa KN, Brar JS, et al. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord. 2000;2:120-130.